Chronic immune-mediated demyelinating polyneuropathy in the setting of cetuximab treatment
Authors:
- Said R. BeydounSBSaid R. Beydoun
- Ron A. ShatzmillerRSRon A. Shatzmiller
- 1 December 2010
- journal article
- case report
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 112 (10) , 900-902
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Invited Article: Inhibition of B cell functionsNeurology, 2008
- A functional role for EGFR signaling in myelination and remyelinationNature Neuroscience, 2007
- Cetuximab induce antibody‐dependent cellular cytotoxicity against EGFR‐expressing esophageal squamous cell carcinomaInternational Journal of Cancer, 2006
- European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve SocietyEuropean Journal of Neurology, 2006
- Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockersNeurology, 2005
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-?Muscle & Nerve, 2000